Innophos takes sales hit as it exits low margin nutrition trading business

By Hank Schultz contact

- Last updated on GMT

Getty Images
Getty Images
Innophos has taken an earnings hit while it continues its transition into a major player in the food and dietary supplement ingredients markets.

In its most recent earnings statement the company, which is based in Cranbury, NJ, said its second quarter 2018 sales had declined by more than 10% year over year, coming in at $185 million. Nevertheless, the company’s aggressive cost cutting and restructuring meant that EBITDA had actually risen in the same time frame.

Ongoing transition

Innophos, until recently, was primarily known as a supplier of speciality industrial phosphates as well as phosphate ingredients used in nutritional applications.  Starting in 2015 with the appointment of Kim Ann Mink, PhD as CEO the company embarked on a program of diversifying the company away from markets that were highly commoditized and which offered little opportunity for innovation.

Mink inaugurated a program for the company she called Vision 2020.  Under the program she led the acquisition of Novel Ingredients and Nutragenesis in 2017. The company spent a combined $143 million on the acquisitions.

Part of those acquisitions included what Innophos characterized as a “low margin nutrition trading”​ business, which the company exited in the second quarter of its fiscal 2019. Mink said the company is pursuing higher margin value added activities, such as the launch of a new vitamin D3 processed with dicalcium phosphate for longer shelf life, or a fruit and vegetable powder blend for an immune health beverage offered in powdered form.  Mink also said Innophos is supplying a “new calcium complete vitamin formulation with magnesium for one of our global customers growing business in Asia.”

The view of stock traders seems to be mixed on Innophos’ new direction.  The company’s shares were trading at almost $50 a share prior to the nutrition acquisitions.  The stock price hit a low of $22.85 late last year.  The company’s shares are trading at slightly more than $28 today.

Related news

Related products

show more

Lonza Inc.

Lonza Inc.

Lonza - Capsugel | 02-Dec-2019 | Product Brochure

Making up 40% of the global population, Aspirationals are defined by their love to shop, desire to consume responsibly and belief that brands should have...

Enzyme-Powered, Plant-Based Antioxidant Ingredient

Enzyme-Powered, Plant-Based Antioxidant Ingredient

Deerland Probiotics & Enzymes | 19-Nov-2019 | Product Catalog

An innovative and totally unique process breaks down the cell wall of organic spinach – something the body struggles to do-- while still preserving the...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars